Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $148.96B
• Dividend Yield: N/A
• Average Volume (3M): 10.77M
• Price to Earnings (P/E): 59.8
• Beta (1Y): 0.79
• Revenue Growth: 21.45%
• EPS Growth: 36.19%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,481,751,600
• 10 Day Avg. Volume: 7,747,840
• 30 Day Avg. Volume: 10,771,159
• PEG Ratio: 4.27
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 7.85
• P/FCF Ratio: 49.69
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 9.30
• Enterprise Value/Gross Profit: 14.71
• Enterprise Value/Ebitda: 36.50
• 1Y Price Target: $125.45
• Price Target Upside: 25.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 25

• Rating: 75 Outperform
• Price Target: $117.00 ▲(17.12% Upside)

Boston Scientific's strong financial performance and positive earnings call sentiment are the primary drivers of its overall score. While technical indicators are mixed, the company's robust growth trajectory and strategic initiatives support a favorable outlook. However, the high valuation suggests caution for potential investors.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Boston Scientific's products, enhancing its market position and supporting long-term financial stability.

Strategic Acquisitions

Strategic acquisitions enhance product offerings and market reach, positioning Boston Scientific for sustained growth in key therapeutic areas.

Cash Flow Management

Efficient cash flow management supports Boston Scientific's ability to invest in R&D and strategic initiatives, ensuring long-term competitiveness.

Negative Factors

Tariff Impacts

Tariff impacts can pressure margins, potentially reducing profitability and affecting Boston Scientific's competitive pricing strategy.

Supply Chain Constraints

Supply chain constraints can hinder product availability and sales growth, challenging Boston Scientific's ability to meet market demand.

Product Discontinuation

Product discontinuation can lead to financial write-offs and disrupt customer relationships, affecting Boston Scientific's market reputation and financial performance.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Boston Scientific generates revenue primarily through the sale of its medical devices across multiple therapeutic areas. The company’s revenue model is primarily based on direct sales to hospitals, healthcare facilities, and clinics, as well as through partnerships with various distributors. Key revenue streams include sales from cardiovascular devices, which encompass coronary and peripheral interventions, as well as rhythm management products such as implantable cardioverter-defibrillators and pacemakers. Additionally, Boston Scientific benefits from recurring revenue through the sale of consumable products and accessories needed for procedures using their devices. The company also invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. Strategic partnerships with healthcare providers and co-development agreements with other medical technology firms further enhance its revenue potential by broadening its product portfolio and market reach.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific exhibits strong financial performance with robust revenue growth, healthy profit margins, and efficient cash management. The company maintains a stable financial position with moderate leverage, positioning it well for future growth.

Income Statement

Boston Scientific has demonstrated strong revenue growth with a 5.36% increase in TTM, supported by healthy gross and net profit margins of 63.23% and 13.53% respectively. The EBIT and EBITDA margins are robust at 18.37% and 23.67%, indicating efficient operational management. Overall, the company shows a positive growth trajectory and profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.54, indicating moderate leverage. The return on equity stands at 11.49%, showcasing effective utilization of equity to generate profits. The equity ratio of 53.94% suggests a solid equity base relative to total assets, contributing to financial stability.

Cash Flow

Cash flow analysis reveals a strong free cash flow growth rate of 15.25% in TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.83 and free cash flow to net income ratio of 0.77 indicate efficient cash conversion and healthy liquidity. Overall, cash flow management appears robust.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.49B	16.75B	14.24B	12.68B	11.89B	9.91B
Gross Profit	11.69B	10.27B	8.83B	7.71B	7.46B	5.58B
EBITDA	4.71B	3.94B	3.45B	2.74B	2.52B	1.51B
Net Income	2.50B	1.85B	1.59B	698.00M	1.04B	-82.00M
Balance Sheet
Total Assets	41.56B	39.40B	35.14B	32.47B	32.23B	30.78B
Cash, Cash Equivalents and Short-Term Investments	534.00M	414.00M	865.00M	928.00M	1.93B	1.73B
Total Debt	12.03B	11.15B	9.49B	9.28B	9.45B	9.54B
Total Liabilities	18.91B	17.39B	15.61B	14.90B	15.61B	15.45B
Stockholders Equity	22.42B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow
Free Cash Flow	3.31B	2.65B	1.70B	914.00M	1.32B	1.13B
Operating Cash Flow	4.29B	3.44B	2.50B	1.53B	1.87B	1.51B
Investing Cash Flow	-6.76B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
Financing Cash Flow	114.00M	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 99.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Neutral. The current price of 99.9 is above the 20-day moving average (MA) of 97.34, below the 50-day MA of 101.15, and below the 200-day MA of 101.56, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 55.10 is Neutral, neither overbought nor oversold. The STOCH value of 89.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$123.04B	26.45	9.72%	2.94%	4.98%	22.08%
SYK	78 Outperform	$145.74B	49.54	14.25%	0.88%	11.36%	-15.66%
ABT	77 Outperform	$225.41B	16.07	―	1.85%	6.37%	―
BSX	75 Outperform	$148.96B	59.83	11.71%	―	21.45%	36.19%
EW	74 Outperform	$44.20B	51.90	15.71%	―	-5.23%	-39.83%
DXCM	71 Outperform	$26.84B	47.91	22.83%	―	9.30%	-14.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Boston Scientific Corporate Events

Boston Scientific Announces Executive Retirement Plan Update

On August 29, 2025, Boston Scientific announced that Jeffrey B. Mirviss will retire from his position as Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. He will continue as a senior advisor until February 27, 2026, receiving a prorated base salary. The company plans to enter into a Retirement Agreement with Mr. Mirviss, ensuring he receives benefits consistent with the company’s Executive Retirement Plan and other incentive programs.

The most recent analyst rating on (BSX) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.